Hello Market Enthusiasts,
 

Our latest spotlight is on a biotech innovator making bold strides and turning heads in the healthcare world. 

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) just delivered significant positive results from its Phase 2a study of MYMD-1® at a prestigious international conference, paving the way for a pivotal Phase 2b trial launching early next year. (7)
 

This groundbreaking work targets a $40 billion global market, addressing critical conditions that affect millions—without any current FDA-approved treatments. (7)
 

Adding to the buzz, TNFA is having a strong day so far, reflecting the growing excitement around its recent progress. 
 

Fueled by cutting-edge science, strong partnerships, and a focused vision, TNF Pharmaceuticals, Inc. is quickly positioning itself as a transformative player in the biotech space.
 

Let’s dive into what makes this company one to watch and the exciting milestones ahead.

(5)

💡 Strategic Partnership at a Premium

Prevail Partners, LLC, a major U.S. life sciences fund, has taken a significant equity position in the company—at a 20% premium to the 30-day VWAP. (4)

This move reflects strong confidence in the company’s groundbreaking science and ambitious vision. 
 

But it doesn’t stop there. The company has also partnered with Prevail InfoWorks, Inc., a globally renowned Clinical Research Organization (CRO), to manage their next Phase 2 clinical trial. (4)

Recognized as a leader in tech-enabled clinical services, Prevail brings unmatched expertise to ensure efficient and impactful trial execution.
 

🔬 Breakthrough Science in Action

At the center of this company’s success is MYMD-1®, an innovative oral drug targeting chronic inflammation and immune-metabolic dysregulation. Early results are already turning heads:

• Sarcopenia Success: Clinical trials met key endpoints, reducing chronic inflammatory markers without adverse effects. 
   
• Expanding Indications: Phase 2 trials are planned for rheumatoid arthritis and Hashimoto’s thyroiditis, creating exciting opportunities in new markets.
   
• Massive Opportunity: With no FDA-approved treatments for sarcopenia, the potential market represents billions annually, addressing critical unmet needs for millions of people. (1)(4)

(6)

🔗 Fully Funded for Success

The company has secured all the funding needed for its clinical trials over the next two years. This financial strength ensures steady progress without disruptions, keeping them on track to hit major milestones and advance their pipeline. (4)
 

🧬 Why This Innovation Matters

This isn’t just another drug in development—it’s the first potential oral TNF-alpha inhibitor, a groundbreaking advancement for treating age-related diseases and chronic inflammation.

🌟 Unmatched Potential: Tackling conditions with no current FDA-approved therapies.

🌍 Global Reach: Addressing diseases like sarcopenia and rheumatoid arthritis, which affect millions worldwide.

🛠️ Strategic Expertise: Partnerships with top-tier CROs ensure the highest standards in trial execution.

(6)

What’s Next?

With strong financial backing, transformative science, and a clear roadmap, this biotech innovator is making waves in healthcare. Every milestone brings them closer to revolutionizing how chronic inflammatory diseases are managed, offering hope to millions.
 

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://finance.yahoo.com/news/tnf-pharmaceuticals-prepares-advance-lead-130000585.html
2. https://finance.yahoo.com/quote/TNFA/
3. https://finance.yahoo.com/quote/TNFA/history/
4. https://ir.tnfpharma.com/
5. https://finance.yahoo.com/news/tnf-pharmaceuticals-announces-strategic-equity-131000995.html
6. https://bit.ly/3ZKkjWj

7. https://finance.yahoo.com/news/tnf-pharmaceuticals-presents-statistically-significant-140000966.html

Data is provided from third-party sources and Market Tips is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized fin.ancial advice, are not finan.cial advisors, and our opinions are not suitable for all in.vest.ors. Please review our full disc.laim.er here. 

Pursuant to an agreement between Momentum Media LLC and Sica Media LLC, Momentum Media LLC has been hired for a period beginning on 12/09/2024 and ending on 12/10/2024 to publicly disseminate information about (TNFA:US) via digital communications. To date we have been paid ten thousand dollars USD. We own zero shares of (TNFA:US).